 Positron tomographic assessment alpha- beta-estradiol uptake metastatic breast carcinoma positron-emitting estrogenic steroid alpha- beta-estradiol FES selective uptake primary breast carcinomas uptake tracer positron emission tomography PET tumor estrogen-receptor concentration use radiopharmaceutical metastases breast carcinoma PET patients clinical radiographic evidence metastatic disease uptake FES PET images metastatic lesions apparent false-positive foci FES uptake patients evaluable PET studies initiation antiestrogen therapy cases decrease FES uptake tumor deposits initiation antiestrogen therapy mean standard deviation dose/ml results PET FES high sensitivity specificity metastatic breast carcinoma additional confirmatory evidence tumor uptake ligand receptor-mediated process